p.99 抽出テキスト

625. Schroder JN, Patel CB, DeVore AD, Bryner BS, Casalinova S, Shah A, et al. Transplantation outcomes with donor hearts after circulatory death. N Engl J Med 2023;388:2121–31. https://doi.org/10.1056/NEJMoa2212438 626. Colvin MM, Smith JM, Ahn YS, Handarova DK, Martinez AC, Lindblad KA, et al. OPTN/SRTR 2022 annual data report: heart. Am J Transplant 2024; 24:S305–93. https://doi.org/10.1016/j.ajt.2024.01.016 627. Schichtel M, Wee B, Perera R, Onakpoya I. The effect of advance care planning on heart failure: a systematic review and meta-analysis. J Gen Intern Med 2020;35:874–84. https://doi.org/10.1007/s11606-019-05482-w 628. Carlisle MA, Fudim M, DeVore AD, Piccini JP. Heart failure and atrial fibrillation, like fire and fury. JACC Heart Fail 2019;7:447–56. https://doi.org/10. 1016/j.jchf.2019.03.005 629. Sartipy U, Dahlstrom U, Fu M, Lund LH. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail 2017;5: 565–74. https://doi.org/10.1016/j.jchf.2017.05.001 630. Mundisugih J, Franke KB, Tully PJ, Munawar DA, Kumar S, Mahajan R. Prevalence and prognostic implication of atrial fibrillation in heart failure subtypes: systematic review and meta-analysis. Heart Lung Circ 2023;32: 666–77. https://doi.org/10.1016/j.hlc.2023.02.009 631. Santhanakrishnan R, Wang N, Larson MG, Magnani JW, McManus DD, Lubitz SA, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation 2016;133:484–92. https://doi.org/10.1161/CIRCULATIONAHA. 115.018614 632. Smit MD, Moes ML, Maass AH, Achekar ID, Van Geel PP, Hillege HL, et al. The importance of whether atrial fibrillation or heart failure develops first. Eur J Heart Fail 2012;14:1030–40. https://doi.org/10.1093/eurjhf/hfs097 633. Teppo K, Lip GYH, Airaksinen KEJ, Halminen O, Haukka J, Putaala J, et al. Comparing CHA2DS2-VA and CHA2DS2-VASc scores for stroke risk stratification in patients with atrial fibrillation: a temporal trends analysis from the retrospective Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) cohort. Lancet Reg Health Eur 2024;43:100967. https://doi.org/10.1016/j.lanepe. 2024.100967 634. Yoshimura H, Providencia R, Finan C, Schmidt AF, Lip GYH. Refining the CHA2DS2VASc risk stratification scheme: shall we drop the sex category criterion? Europace 2024;26:euae280. https://doi.org/10.1093/europace/ euae280 635. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857–67. https://doi.org/10.7326/0003-4819-146- 12-200706190-00007 636. Vilches S, Fontana M, Gonzalez-Lopez E, Mitrani L, Saturi G, Renju M, et al. Systemic embolism in amyloid transthyretin cardiomyopathy. Eur J Heart Fail 2022;24:1387–96. https://doi.org/10.1002/ejhf.2566 637. Guttmann OP, Rahman MS, O’Mahony C, Anastasakis A, Elliott PM. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart 2014;100:465–72. https://doi.org/10.1136/ heartjnl-2013-304276 638. Guttmann OP, Pavlou M, O’Mahony C, Monserrat L, Anastasakis A, Rapezzi C, et al. Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA). Eur J Heart Fail 2015;17:837–45. https://doi. org/10.1002/ejhf.316 639. Hirota T, Kubo T, Baba Y, Ochi Y, Takahashi A, Yamasaki N, et al. Clinical profile of thromboembolic events in patients with hypertrophic cardiomyopathy in a regional Japanese cohort—results from Kochi RYOMA study. Circ J 2019; 83:1747–54. https://doi.org/10.1253/circj.CJ-19-0186 640. Hsu JC, Huang YT, Lin LY. Stroke risk in hypertrophic cardiomyopathy patients with atrial fibrillation: a nationwide database study. Aging (Albany NY) 2020;12:24219–27. https://doi.org/10.18632/aging.104133 641. Lozier MR, Sanchez AM, Lee JJ, Donath EM, Font VE, Escolar E. Thromboembolic outcomes of different anticoagulation strategies for patients with atrial fibrillation in the setting of hypertrophic cardiomyopathy: a systematic review. J Atr Fibrillation 2019;12:2207. https://doi.org/10. 4022/jafib.2207 642. Lee SE, Park JK, Uhm JS, Kim JY, Pak HN, Lee MH, et al. Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy. Heart 2017;103:1496–501. https://doi.org/10.1136/heartjnl-2016-310720 643. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955–62. https://doi.org/10.1016/ S0140-6736(13)62343-0 644. Savarese G, Giugliano RP, Rosano GM, McMurray J, Magnani G, Filippatos G, et al. Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis. JACC Heart Fail 2016;4: 870–80. https://doi.org/10.1016/j.jchf.2016.07.012 645. Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GY. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. Eur J Heart Fail 2015;17:1192–200. https://doi.org/10.1002/ejhf.343 646. von Lueder TG, Atar D, Agewall S, Jensen JK, Hopper I, Kotecha D, et al. All-cause mortality and cardiovascular outcomes with non-vitamin K oral anticoagulants versus warfarin in patients with heart failure in the Food and Drug Administration Adverse Event Reporting System. Am J Ther 2019;26: e671–8. https://doi.org/10.1097/MJT.0000000000000883 647. Boersma LV, Schmidt B, Betts TR, Sievert H, Tamburino C, Teiger E, et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J 2016;37:2465–74. https://doi.org/10.1093/eurheartj/ ehv730 648. Reddy VY, Mobius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study with Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol 2013;61:2551–6. https://doi.org/10.1016/j. jacc.2013.03.035 649. Potpara T, Grygier M, Haeusler KG, Nielsen-Kudsk JE, Berti S, Genovesi S, et al. An international consensus practical guide on left atrial appendage closure for the non-implanting physician: executive summary. Thromb Haemost 2025;125:825–46. https://doi.org/10.1055/a-2469-4896 650. Oliva A, Ioppolo AM, Chiarito M, Cremonesi A, Azzano A, Micciche E, et al. Left atrial appendage closure compared with oral anticoagulants for patients with atrial fibrillation: a systematic review and network meta-analysis. J Am Heart Assoc 2024;13:e034815. https://doi.org/10.1161/JAHA.124.034815 651. Das S, Lorente-Ros M, Wu L, Mehta D, Suri R. Safety of left atrial appendage closure in heart failure patients. J Cardiovasc Electrophysiol 2022;33: 2578–84. https://doi.org/10.1111/jce.15682 652. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 2020;383:1305–16. https://doi.org/10.1056/NEJMoa2019422 653. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358:2667–77. https://doi.org/10.1056/NEJMoa0708789 654. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834–40. https://doi.org/10. 1056/NEJMoa021375 655. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825–33. https://doi.org/10.1056/ NEJMoa021328 656. Zafeiropoulos S, Doundoulakis I, Bekiaridou A, Farmakis IT, Papadopoulos GE, Coleman KM, et al. Rhythm vs rate control strategy for atrial fibrillation: a meta-analysis of randomized controlled trials. JACC Clin Electrophysiol 2024;10:1395–405. https://doi.org/10.1016/j.jacep.2024.03.006 657. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003;41:1690–6. https://doi.org/10.1016/s0735- 1097(03)00332-2 658. Kelly JP, DeVore AD, Wu J, Hammill BG, Sharma A, Cooper LB, et al. Rhythm control versus rate control in patients with atrial fibrillation and heart failure with preserved ejection fraction: insights from Get With the Guidelines— Heart Failure. J Am Heart Assoc 2019;8:e011560. https://doi.org/10.1161/ JAHA.118.011560 659. Sartipy U, Savarese G, Dahlstrom U, Fu M, Lund LH. Association of heart rate with mortality in sinus rhythm and atrial fibrillation in heart failure with preserved ejection fraction. Eur J Heart Fail 2019;21:471–9. https://doi.org/10. 1002/ejhf.1389 660. Li SJ, Sartipy U, Lund LH, Dahlstrom U, Adiels M, Petzold M, et al. Prognostic significance of resting heart rate and use of beta-blockers in atrial fibrillation and sinus rhythm in patients with heart failure and reduced ejection fraction: findings from the Swedish Heart Failure Registry. Circ Heart Fail 2015;8: 871–9. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002285 661. Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B, Hagens VE, et al. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace 2006; 8:935–42. https://doi.org/10.1093/europace/eul106 662. Hess PL, Sheng S, Matsouaka R, DeVore AD, Heidenreich PA, Yancy CW, et al. Strict versus lenient versus poor rate control among patients with atrial fibrillation and heart failure (from the Get With the Guidelines—Heart Failure Downloaded from academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag100/8766302 by guest on 31 August 2026